Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 9/20 | 0.56 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246945 | 0.92 | PPARG (0.59) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL4251659 | 0.89 | PPARG (0.58) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL4244806 | 0.88 | KDM4E (0.58) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL4250994 | 0.88 | KDM4E (0.58) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL4244821 | 0.88 | KDM4E (0.58) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL4254702 | 0.80 | KDM4E (0.55) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL4250885 | 0.80 | KDM4E (0.55) | PPARGKDM4EALOX15TSHRTDP1 | |
| SCHEMBL5935707 | 0.77 | PPARG (0.69) | PPARGKDM4EALOX15TSHRTDP1 | |
| Balaglitazone SCHEMBL20125574 | 0.77 | PPARG (1.00) | PPARGKDM4EALOX15TSHRTDP1 | |
| Balaglitazone SCHEMBL20125575 | 0.77 | PPARG (1.00) | PPARGKDM4EALOX15TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012069-A1 | Novel Antidiabetic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| EP-1781633-A1 | NOVEL ANTIDIABETIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2007-05-09 | — | — | EP | claimed |
| WO-2006018855-A1 | NOVEL ANTIDIABETIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2006-02-23 | — | — | WO | claimed |
| US-20090012069-A1 | Novel Antidiabetic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
| EP-1781633-A1 | NOVEL ANTIDIABETIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018855-A1 | NOVEL ANTIDIABETIC COMPOUNDS | CADILA HEALTHCARE LIMITED (IN) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012069-A1 | Novel Antidiabetic Compounds | GPR119, SLC5A1, SLC5A2 | PPARG 76/4885KDM4E 3658/4885ALOX15 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.